This position is listed on behalf of a partner company, who manages all applications and next steps. Our partner is looking for an Executive Director, Asset Strategy Leadership based in the United States. This senior leadership role will shape the strategic direction of clinical-stage assets across oncology and immunology/inflammation. You’ll translate complex scientific, competitive, clinical, and computational insights into clear portfolio decisions and asset strategies. Working across discovery, clinical development, platform, business development, finance, and technology teams, you’ll help determine where resources can create the greatest impact. The role combines deep scientific expertise with commercial and strategic judgment to strengthen asset differentiation and portfolio value. You’ll leverage advanced computational approaches, proprietary data, and AI-enabled insights to inform drug development and clinical decision-making. As a senior strategic partner, you’ll communicate high-stakes recommendations to executive leaders and external stakeholders with clarity and conviction. This remote U.S. opportunity offers the chance to influence the advancement of transformative medicines for patients with significant unmet needs. Accountabilities: As an Executive Director, Asset Strategy Leadership, you will provide strategic direction across clinical-stage assets, integrating scientific, competitive, clinical, financial, and market perspectives to guide portfolio decisions. Define and drive asset strategy for small-molecule clinical programs in oncology and immunology/inflammation. Integrate competitive positioning, mechanistic differentiation, biomarker strategy, and patient segmentation into asset-level strategies. Support go/no-go, prioritization, and portfolio decisions by translating complex scientific and market information into clear strategic recommendations. Leverage computational approaches, proprietary data, and AI-enabled insights to strengthen asset positioning and clinical development strategies. Develop and pressure-test competitive narratives for portfolio assets, building evidence to inform leadership decisions, partnership discussions, and investor communications. Partner with leaders across clinical development, discovery, platform, ClinTech, business development, and finance to align resources with strategic priorities. Evaluate portfolio trade-offs and contribute to decisions involving resource allocation, asset valuation, and development priorities. Identify opportunities to improve how clinical assets are differentiated, advanced, and positioned for patients with significant unmet needs. Promote cross-functional alignment and efficient collaboration across scientific, technical, and business teams. Serve as a senior strategic partner to functional leaders, helping translate scientific complexity into actionable decisions. Communicate strategic recommendations with executive-level clarity and confidence to internal leadership and external partners. Continuously evaluate emerging data, competitive dynamics, technologies, and development trends to strengthen asset strategies and portfolio outcomes. Requirements: The ideal candidate combines deep expertise in drug discovery and development with extensive experience leading clinical assets strategically, particularly within small-molecule therapeutics and complex therapeutic areas. PhD in life sciences or a related scientific discipline, with deep expertise in drug discovery and development. 10+ years of experience in biotechnology or pharmaceutical organizations. Proven track record of asset-level strategic leadership and advancing programs through clinical stage gates with demonstrable impact on portfolio value. Deep expertise in the development of small-molecule therapeutics for oncology and immunology/inflammation. Experience in rare disease is a plus. Demonstrated ability to use computational approaches and data-driven platforms to strengthen asset strategy and clinical decision-making. Strong understanding of competitive positioning, mechanistic differentiation, biomarker strategies, patient segmentation, regulatory considerations, and market dynamics. Proven ability to build and articulate compelling strategic and competitive cases for clinical-stage assets. Strong financial acumen, with the ability to engage credibly in discussions around resource allocation, asset valuation, and portfolio trade-offs. Exceptional executive presence and the ability to synthesize complex scientific and business information into clear, conviction-led recommendations. Strong communication and stakeholder management skills, with the ability to influence senior leadership and external partners. Collaborative, analytical, adaptable, and execution-oriented approach to working across functional and organizational boundaries. Benefits: Remote position based in the United States. Required periodic travel. Annual base salary of $287,900–$356,400 for New York City, Boston, and San Francisco Bay Area locations. Annual base salary of $261,800–$314,600 for Salt Lake City and all other U.S. locations. Annual bonus eligibility. Equity compensation. Comprehensive benefits package. Opportunity to work at the intersection of AI, computational biology, drug discovery, and clinical development. Cross-functional environment spanning scientific, clinical, technology, platform, business development, and finance teams. Opportunity to contribute to the development of medicines addressing significant unmet patient needs. Culture centered on integrity, ownership, curiosity, collaboration, continuous learning, and urgency around patient impact. Equal opportunity workplace with accommodations available throughout the selection process.